Track Eledon Pharmaceuticals's receivables ($0) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Eledon Pharmaceuticals (ELDN) currently reports a receivables of $0 as of June 2026. That compares with $710K in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Eledon Pharmaceuticals's receivables history and peer comparisons.
Eledon Pharmaceuticals's receivables decreased from $710K to $0 — a 100.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Eledon Pharmaceuticals reported $0 in receivables as of June 2026. That compares with $710K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eledon Pharmaceuticals, and consider following ELDN for alerts when major investors trade the stock.
Eledon Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ELDN with unrelated industries.